SEC61A1 and Miyoshi myopathy: Mutations in the Sec61α gene sequence resulting in loss of inhibitor binding, such as those introduced experimentally in cancer cell lines in previous research (Baron et al, 2016; Gérard et al, 2020), may also confer MM tumors with resistance to Sec61 inhibitors.